MPM Capital

Blade Therapeutics is a discovery stage drug development company. Their mission is to create antifibrotic treatment strategies that address a wide variety of congenital and acquired diseases of fibrosis. Their leadership team has extensive experience at developing drugs that treat fibrotic disorders. They are also partnering with international experts in order to identify and in-license cutting-edge technologies to build a robust pipeline of antifibrotic compounds.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

SAI is an ideal drug discovery, development and manufacturing partner. Their pharma and biotech clients gain clear competitive advantages through shorter time to market and risk minimization using their integrated and high-quality scientific services. SAI’s mission is to help their partners develop innovative medicines quicker and at lower cost by providing reliable research and manufacturing solutions. Their guiding principles are to be reliable, communicate effectively, safeguard IP, invest in people and to adopt technologies. At SAI Life Sciences, developing a business relationship with their clients that benefits both parties is only the beginning. They have learned through experience, it is when they build a partnership with a customer, that they can truly amplify their mutual interests and successes. At SAI they will call this “+1” and it hints at the additional value they aim to find mutually in longer term relationships.

Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.

Peplin is a development-stage specialty pharmaceutical company focused on advancing and commercializing medical dermatology products. The Company is developing PEP005 (ingenol mebutate) (PEP005), which is derived from Euphorbia peplus (E. peplus), a plant referred to as petty spurge or radium weed. Peplin’s lead product candidate, which is in Phase III clinical trials, is a patient-applied topical gel containing PEP005, a compound used for the treatment of actinic keratosis (AK). Peplin’s other product candidate is a physician-applied topical gel for the treatment of superficial basal cell carcinoma (superficial BCC), PEP005 Gel for BCC. The active compound in each product is a small molecule extracted and purified from the sap of E. peplus. On October 16, 2008, the Company acquired Neosil, Inc., a dermatology-focused company. Later on, Peplin, Inc. was acquired by LEO Pharma A/S.

Protego Biopharma, Inc. engages in the research and development of therapeutics and diagnostics using human genetic links. It offers products in the areas of rare diseases associated with amyloidosis; early diagnosis for amyloidosis; and novel platform enabling compound screening. Protego Biopharma, Inc. was formerly known as MisfoldingDiagnostics. The company was incorporated in 2011 and is based in San Diego, California.

Xoft, Inc. develops electronic brachytherapy (eBx) systems for radiation oncology applications. It offers Axxent Controller that utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed. The company also provides Axxent balloon applicator, a treatment solution for accelerated partial breast irradiation; Axxent vaginal applicator that enables radiation oncologists to perform vaginal brachytherapy; and Axxent surface applicator that enables radiation oncologists to treat surface lesions. In addition, it offers accessories, such as physics accessory kits, personnel protective shields, procedure accessory packs, patient care kits, applicator clamp and base plates, and vacuum pumps, as well as FlexiShield, which drapes over the patient treatment area to reduce radiation transmission to nearby healthy tissue and organs. The company's products are used to treat early stage breast cancer, skin cancer, and endometrial cancer. It offers its products through physicians and distributors in Europe. Xoft, Inc. was formerly known as Xoft microTube, Inc. and changed its name in September 2004. The company was founded in 1998 and is based in Sunnyvale, California.

Amphivena Therapeutics, Inc. develops bifunctional antibody therapies for hematologic malignancies. It eradicates blood cancers with a therapy that harnesses the patient’s own immune system to destroy tumor cells and their precursors. Amphivena Therapeutics, Inc. was formerly known as Affimed Spinco Inc. The company was founded in 2012 and is based in San Francisco, California. Amphivena Therapeutics, Inc. operates as a subsidiary of Affimed N.V.

Vascular Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutics for treating patients with type 1 and type 2 diabetes. It focuses on the development of VPI-2690B, a subcutaneously administered monoclonal antibody that is stimulated by hyperglycemia for the treatment of diabetic nephropathy. The company was founded in 2005 and is based in Research Triangle Park, North Carolina.

On June 30, 2020, Valeritas Holdings, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.

PrimeraDx, Inc. offers multiplexed infectious disease assays. It provides Scalable Target Amplification Routine technology, which is a method for simultaneous quantitative measurement of multiple target nucleic acids. The company also offers ViraQuant, a multiplexed assay providing quantitative and simultaneous measurement of viruses; and FungiQuant Yeast and FungiQuant Mold, which are fungal panels for mycology testing. Its products are used in miRNA, DNA methylation, quantitative genotyping, gene expression, and viral load measurement applications. PrimeraDx, Inc. was founded in 2004 and is based in Mansfield, Massachusetts.

Established in 1999, Restore Medical is a privately-held company focused on becoming the primary resource for physicians specializing in sleep and breathing disorders. Restore Medical has developed and markets proprietary implant technology which addresses such disorders as snoring and sleep apnea. The company's first product based on this technology, the patented Pillar™ System, received market clearance from the Food and Drug Administration in late 2002 and is currently available throughout the United States. Restore Medical also distributes other related high-quality products to the Ear, Nose and Throat physicians through our dedicated sales team. Located in St. Paul, Minnesota, Restore Medical manufactures the Pillar™ System in its onsite state-of-the-art Class 100,000 Clean Room. The company is ISO 9001 certified and utilizes an intranet-based quality and product development system. Restore currently employs a team of approximately 55 professionals.

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

Neosil, Inc. is a dermatology-focused pharmaceutical company with a developed topical hair growth product and that is developing a broad-spectrum topical anti-microbial agent for acne and anti-infective use.

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer.

Werewolf Therapeutics operates as an oncology biotherapeutics company advancing a pipeline of transformative cancer treatments. Werewolf Therapeutics is developing medicines designed to be delivered systemically, but remain inactive in the body until they reach the tumor microenvironment, where they stimulate a powerful immune response and unleash an attack on cancer cells.

QuatRx Pharmaceuticals Company, a biopharmaceutical company, engages in discovering, licensing, developing, and commercializing compounds in the areas of endocrine, metabolic, and cardiovascular therapeutics. Its products include Osphena for the treatment for vaginal atrophy, a common problem associated with estrogen deficiency in post-menopausal women. QuatRx Pharmaceuticals Company was founded in 2000 and is based in Ann Arbor, Michigan.

On June 30, 2020, Valeritas Holdings, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.

EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0 procedure—a minimally invasive solution that addresses a significant unmet clinical need. EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington.

TriVascular, Inc. is a medical device company that engages in the research, design, and manufacture of technologies for endovascular aortic repair in the United States and internationally. It offers endovascular grafts and self-expanding stent grafts; Ovation and Ovation Prime Stent Graft for treating abdominal aortic aneurysms; polymer-filled sealing rings to preserve the proximal neck; and Size My Patient Tool to review patient images for device and case planning recommendations. TriVascular, Inc. was formerly known as Boston Scientific Santa Rosa Corp. The company was founded in 1998 and is based in Santa Rosa, California. As of March 31, 2008, TriVascular, Inc. operates as a subsidiary of TriVascular Technologies, Inc.

Atopix Therapeutics Limited is a privately held, clinical-stage, biopharmaceutical company based in Oxford, UK, with an innovative approach to allergy. The company is developing a novel class of oral anti-allergic medicines, called CRTH2 antagonists, to treat atopic dermatitis, asthma and allergic rhinitis. Its lead candidate is currently being studied in a Phase 2 clinical trial for moderate to severe atopic dermatitis in several leading European dermatology centres.

Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.

InformedDNA optimizes genetics-related healthcare spending and patient care by improving access to clinical and scientific genomics expertise. We are the nation’s largest independent provider network of genetics specialists enabled by a comprehensive evidence-based knowledge library for genetic tests and hereditary conditions We employ the largest full-time staff of independent, objective genetics specialists in the nation. Our high-touch, technologically-advanced approach sets us apart — and sets our customers apart. We are a partner to health plans, an advisor to health systems and providers, and an advocate for patients. Direct access to our experts empowers you to provide personalized, cutting-edge care while optimizing healthcare spending. Working with InformedDNA means connecting directly with our team and genetics resources. We’re true partners. At the core of our services, we’re committed to patients getting the right tests that lead to better care. Everyone benefits from informed decisions.

Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases. The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).

Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells. The company's drugs combine a proprietary high throughput gene-editing and target discovery method with high-resolution protein crystallography, computational biology and clinical informatics, enabling patients to improve cancer treatment both with single therapy and in combination with existing drugs and treatments.

Xoft, Inc. develops electronic brachytherapy (eBx) systems for radiation oncology applications. It offers Axxent Controller that utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed. The company also provides Axxent balloon applicator, a treatment solution for accelerated partial breast irradiation; Axxent vaginal applicator that enables radiation oncologists to perform vaginal brachytherapy; and Axxent surface applicator that enables radiation oncologists to treat surface lesions. In addition, it offers accessories, such as physics accessory kits, personnel protective shields, procedure accessory packs, patient care kits, applicator clamp and base plates, and vacuum pumps, as well as FlexiShield, which drapes over the patient treatment area to reduce radiation transmission to nearby healthy tissue and organs. The company's products are used to treat early stage breast cancer, skin cancer, and endometrial cancer. It offers its products through physicians and distributors in Europe. Xoft, Inc. was formerly known as Xoft microTube, Inc. and changed its name in September 2004. The company was founded in 1998 and is based in Sunnyvale, California.

Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.

Synergia Pharma Inc. operates as a biopharmaceutical company.

QuatRx Pharmaceuticals Company, a biopharmaceutical company, engages in discovering, licensing, developing, and commercializing compounds in the areas of endocrine, metabolic, and cardiovascular therapeutics. Its products include Osphena for the treatment for vaginal atrophy, a common problem associated with estrogen deficiency in post-menopausal women. QuatRx Pharmaceuticals Company was founded in 2000 and is based in Ann Arbor, Michigan.

Iconic Therapeutics, Inc. operates as a biopharmaceutical company that translates tissue factor biology in angiogenesis, inflammation, and metastasis to develop new therapeutics for retinal disease and cancer. Its products include ICON-1, a fusion protein designed to address the basis of vision loss in age-related macular degeneration. Iconic Therapeutics, Inc. was incorporated in 2002 and is based in South San Francisco, California.

Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.

TriVascular, Inc. is a medical device company that engages in the research, design, and manufacture of technologies for endovascular aortic repair in the United States and internationally. It offers endovascular grafts and self-expanding stent grafts; Ovation and Ovation Prime Stent Graft for treating abdominal aortic aneurysms; polymer-filled sealing rings to preserve the proximal neck; and Size My Patient Tool to review patient images for device and case planning recommendations. TriVascular, Inc. was formerly known as Boston Scientific Santa Rosa Corp. The company was founded in 1998 and is based in Santa Rosa, California. As of March 31, 2008, TriVascular, Inc. operates as a subsidiary of TriVascular Technologies, Inc.

ElevateBio is a operator of a portfolio of cell and gene therapy companies intended to develop, manufacture and commercialize life-transforming medicines. The company creates a portfolio through partnerships with the world's most innovative scientists and inventors as well as it created a centralized facility that integrates all the elements that translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases.

Hypnion is a neuroscience drug discovery and development company that develops novel therapeutics for the treatment of central nervous system disorders. The company develops treatments for sleep- and wake-alertness disorders and circadian rhythm abnormalities. Hypnion offers SCORE-2004, a drug discovery platform that is able to measure drugs’ impact on sleep and wake parameters. Hypnion is acquired by Eli Lilly and Company. Hypnion was founded in 2000 and is based in Worcester, Massachusetts.

SeqLL True Single Molecule Sequencing | DNA & RNA Sequencing Services

Cerimon Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for autoimmune diseases, inflammation, and pains in the United States and Europe. It develops Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, including pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. Cerimon Pharmaceuticals, Inc. was founded in 2004 and is headquartered in South San Francisco, California.

ForteBio is a venture-capital funded life science company developing analytical systems to provide rapid, real-time results for protein quantification or characterization of protein-protein interaction. These systems enable real-time analysis of biomolecular interactions in micro-volume sample sizes, providing information on affinity, kinetics, and concentration.

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis, and other hematologic disorders and inflammation in Europe and the United States. Its lead product Andexxa, an antidote for the treatment of rivaroxaban and apixaban under the Ondexxya Brand. The company offers Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients for an acute medical illness. It also develops cerdulatinib, an investigational oral, dual spleen tyrosine kinase, and janus kinases inhibitor for the treatment of hematologic cancers; and Syk inhibitors. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Daiichi Sankyo, Inc.; Bayer Pharma, AG; Takeda, Ora, Inc.; Astellas Pharma Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 2003 and is headquartered in South San Francisco, California. As of July 1, 2020, Portola Pharmaceuticals, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Potenza Therapeutics, Inc. is a preclinical-stage biotechnology company focused on building a portfolio of oncology programs that utilize the body’s own immune system to seek out, recognize and destroy tumors through a diversity of mechanisms that influence tumor immunity. It was founded in 2014 and headquartered in Cambridge, Massachusetts.

Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor, in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor. Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.

Maverick Therapeutics is a biotech company focused on improving the lives of patients with solid tumor cancers by developing breakthrough T cell immunotherapies with improved safety and efficacy. Their highly innovative platform, COBRA™, is the most advanced bispecific T cell engaging platform in its class, designed to safely target solid tumors with highly specific and potent activity.

QuatRx Pharmaceuticals Company, a biopharmaceutical company, engages in discovering, licensing, developing, and commercializing compounds in the areas of endocrine, metabolic, and cardiovascular therapeutics. Its products include Osphena for the treatment for vaginal atrophy, a common problem associated with estrogen deficiency in post-menopausal women. QuatRx Pharmaceuticals Company was founded in 2000 and is based in Ann Arbor, Michigan.

TriNetX is the global health research network enabling healthcare organizations, biopharmaceutical companies and contract research organizations (CROs) to collaborate, enhance trial design, improve site selection and planning, and bring new therapies to market faster. TriNetX combines real time access to longitudinal clinical data with state-of-the-art analytics to answer complex research questions at the speed of thought. The TriNetX platform is HIPAA and GDPR compliant.

ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and develop first-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations. ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. The company was founded in 2015 and is based in Dallas, Texas.

Archus Orthopedics is focused on the development of implants to treat a variety of spine disorders that result from degenerative changes in the facet joints. Archus Orthopedics offers Total Facet Arthroplasty System, a spinal implant that is designed for patients suffering from lumbar spinal stenosis. Archus Orthopedics was acquired by Facet Solutions in November 2009. Archus Orthopedics was founded in 2001 and is based in Redmond, Washington.

In December 1999, Pangea Systems became DoubleTwist, Inc. - a new application service provider (ASP)/ Internet company devoted to empowering life scientists. The change reflects a new focus on this Internet portal. DoubleTwist.com integrates powerful tools and data behind automated research agents that retrieve and interpret data based on the user's scientific questions. The company's traditional data warehousing and mining software power the site, enabling life science research through an easy-to-use interface on the Web. DoubleTwist has established a talented and experienced development team of scientific and technical personnel dedicated to building software solutions that address the biological data management needs of life scientists. DoubleTwist's scientific team is comprised of leading experts in their respective fields of biochemistry, molecular biology, protein chemistry, bioinformatics, computer science and computational biology. They come to DoubleTwist from world-renowned institutions, including Stanford University, UCLA, UC Berkeley, UCSF, University of Pennsylvania, Sandoz Pharmaceutical, Onyx Pharmaceutical, Incyte, Molecular Simulations, Molecular Dynamics, Roche and Glaxo Wellcome. The company's software engineers have extensive experience in commercial-grade software systems, with particular expertise in relational database and object-oriented development. They come to DoubleTwist from some of the industry's most successful companies, including Apple, Oracle and IBM.

Alinea Pharmaceuticals, Inc., a biopharmaceutical company previously focused on developing new therapeutics for the treatment of diabetes and other metabolic disorders.

We are using induced pluripotent stem cells for drug discovery and development. Focused on neurodegenerative diseases such as SMA, ALS and Parkinson's, and other major unmet medical needs.

Pierian Biosciences technology platforms are currently undergoing optimization so they will be able to deliver specific, actionable, personalized information regarding the most appropriate chemotherapeutic, biologic, and/or immunotherapeutic cancer treatment for each patient. With this valuable information, providers will be able to design patient-specific strategies that enhance the quality of life for cancer patients.

Pacira Pharmaceuticals Inc. operates as a pharmaceutical company which engages in the development and manufacturing of injectable pharmaceutical products. Pacira Pharmaceuticals Inc. was formerly known as DepoTech Corp. was formerly as SkyePharma Inc. and changed its name to Pacira Pharmaceuticals Inc. in June, 2007. The company was founded in 1989 and is based in San Diego, California. Pacira Pharmaceuticals Inc. operates as a subsidiary of Pacira, Inc.

MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases. The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company's Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology. The company was founded in 2000 and is headquartered in Rockville, Maryland.

Aires Pharmaceuticals, Inc., a clinical stage pharmaceutical company, develops therapies to treat pulmonary disorders. The company offers Aironite, an inhaled drug that is used to treat adult and pediatric pulmonary hypertension, cystic fibrosis, pneumonia, and other respiratory infections. It also develops products for the treatment of bacterial pulmonary infections. Aires Pharmaceuticals was founded in 2006 and is based in San Diego, California.

CoStim Pharmaceuticals Inc. operates as a biotechnology company. It develops antibody agents for treatment of cancer. The company was incorporated in 2011 and is based in Boston, Massachusetts.

Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Entrada Therapeutics, Inc., a biotechnology company, engages in the treatment of diseases through the intracellular delivery of biologic. The company enables intracellular delivery of proteins, peptides, and nucleic acids and allows development of programs across intracellular target classes. Its Intracellular enzyme replacement therapy (IC-ERT) is a medical treatment that corrects an enzyme deficiency in the cell, Protein-Protein Interaction Inhibitors. The company was founded in 2016 and is based in Boston, Massachusetts.

Neuromed Pharmaceuticals is focused on the development, production, and marketing of pain therapies in Canada and the United States. Neuromed Pharmaceuticals was acquired by Zalicus in December 2009. Neuromed Pharmaceuticals was founded in 1998 and is based in Vancouver, Canada.

Astute Medical, Inc., a life science tools company, discovers and develops protein biomarkers to serve as the basis for novel diagnostic tests for conditions that require rapid diagnosis and risk assessment. The company focuses on prognostic biomarker validation. It offers NephroCheck, a single use cartridge to detect biomarkers of acute kidney injury. The company also provides Astute140, a meter that converts fluorescent signal from NephroCheck test cartridge into a single numerical result. It sells its products in the United States and Europe. Astute Medical, Inc. was founded in 2007 and is based in San Diego, California with a location in Paris, France. As of April 4, 2018, Astute Medical, Inc. operates as a subsidiary of bioMérieux S.A.

23andMe, Inc. provides consumer genetics and research services. The company offers DNA analysis services through home-based saliva collection kit for consumers to access and understand the human genome. Its services include Health + Ancestry, a genetic insight into ancestry, traits, and health; and Ancestry + Traits, a DNA kit with an ancestry breakdown and 30+ trait reports. The company was founded in 2006 and is based in Sunnyvale, California. With an additional office in Mountain View, California.

Amphora Discovery Corporation operates as a biotechnology company. It provides integrated services to the pharmaceutical industry. The company's products and services include in vitro assay protocols, in vitro throughput screening and compound profiling services, custom assay development, enzymology services, and lead discovery/lead optimization partnering programs. It offers drug discovery contract research services, HTS, profiling and lead generation, and lead optimization solutions. The company serves pharmaceutical and biopharmaceutical companies, emerging biotechnology companies, and research foundations. Amphora Discovery Corporation was founded in 2001 and is headquartered in Durham, North Carolina. As of July 2008, Amphora Discovery Corporation operates as a subsidiary of Nanosyn Inc.

Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases. The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).

Peptimmune is a privately held clinical stage biotechnology company focused on utilizing both novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders. The company is developing second generation therapeutics that are expected to result in safer and more effective products for obesity, multiple sclerosis, rheumatoid arthritis and pemphigus vulgaris.

EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0 procedure—a minimally invasive solution that addresses a significant unmet clinical need. EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington.

CryoCor, Inc. is a medical technology company headquartered in San Diego, California developing products that use cryogenic technology to treat cardiac rhythm disorders called arrhythmias. Cardiac cryoablation is a non-surgical, minimally-invasive procedure in which a cardiologist inserts a catheter into a blood vessel in the leg of an afflicted individual and advances it into the heart. Once it reaches the targeted cardiac tissue, the catheter tip temperature is lowered to approximately -90°C — thereby blocking the conduction of the abnormal signals causing the heart to beat inappropriately and restoring its function to normal. The CryoCor™ Cardiac Cryoablation System consists of a cryoablation catheter that is connected to an articulating arm mounted on the company’s refrigeration console. To facilitate catheter placement, the System can be used in conjunction with CryoCor introducer sheaths. The System has been approved for use in Europe and has been commercially available there since 2002. CryoCor's European activities are managed by its wholly-owned subsidiary in Cologne, Germany which directs the company's marketing, sales and post-market clinical activities. The CryoCor Cardiac Cryoablation System is currently in use at multiple medical centers throughout Europe.

PrimeraDx, Inc. offers multiplexed infectious disease assays. It provides Scalable Target Amplification Routine technology, which is a method for simultaneous quantitative measurement of multiple target nucleic acids. The company also offers ViraQuant, a multiplexed assay providing quantitative and simultaneous measurement of viruses; and FungiQuant Yeast and FungiQuant Mold, which are fungal panels for mycology testing. Its products are used in miRNA, DNA methylation, quantitative genotyping, gene expression, and viral load measurement applications. PrimeraDx, Inc. was founded in 2004 and is based in Mansfield, Massachusetts.

Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.

Tetherex Pharmaceuticals Corporation, a clinical-stage development biopharmaceutical company, focuses on development of therapeutics for the treatment of inflammation, thrombosis, and tumor metastasis across a broad range of severe diseases in Oklahoma City, Oklahoma. It focuses on developing SelK2, a humanized monoclonal antibody. The company was founded in 2014 and is based in Oklahoma City, Oklahoma with an additional office in Morrisville, North Carolina.

Founded in 2003, Accelerator Corporation is a Seattle-headquartered private equity firm with an office in New York and San Diego. The firm is focused on early-stage investments in biotechnology companies.

Innovative Spinal Technologies is a spine technology company that develops motion preservation and minimally invasive treatments for spinal disorders. Its products include AXIENT Dynamic Fixation system, a pedicle screw-based motion system, PARAMOUNT Lumbar Fusion System, which is engineered for lumbar fusion procedures conducted in a minimally invasive, mini-open, or open fashion, PARAMOUNT MIS Pedicle Screw System for single and multi-level procedures, PARAMOUNT Open Pedicle Screw System, which is designed to meet the needs of minimally invasive lumbar fusion, and PARAMOUNT VBR, which is designed for a minimally invasive transforaminal approach. Innovative Spinal Technologies was founded in 2002 and is headquartered in Mansfield, Massachusetts

Arriva Pharmaceuticals, Inc., founded in 1997, is a privately held biopharmaceutical company focused on the development and commercialization of recombinant protease inhibitors for treatment of a wide range of human diseases. The areas of therapeutic focus are: - Respiratory diseases: hereditary emphysema, asthma, chronic obstructive pulmonary disorder (COPD) and cystic fibrosis. - Dermatological diseases: atopic dermatitis, psoriasis. - Inflammatory ear diseases: otitis media, otitis externa. - Oncology: breast cancer, prostate cancer. The company has developed technology for large-scale production of stable, non-animal sourced recombinant proteins in yeast. Using this technology, GMP, Good Manufacturing Practice, clinical grade recombinant alpha 1-antitrypsin (AAT) has been produced for clinical trials for respiratory and dermatological indications and maspin will be produced for treatment of breast and prostate cancer. In January, 2001 the company changed its name from AlphaOne Pharmaceuticals, Inc. to Arriva Pharmaceuticals, Inc. to reflect an expansion from a single product focus to a more diversified drug product pipeline.

AVEO is a late-stage biopharmaceutical company focused on the discovery and development of targeted cancer therapeutics. AVEO's proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR, ErbB3 and NOTCH), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough and Biogen Idec.

BioIntervene, Inc. is a preclinical-stage biopharmaceutical company committed to the discovery and development of effective and non-addictive medicines for chronic pain and other chronic inflammatory and neurodegenerative disorders. The Company was founded in 2014 based on insights from research at Saint Louis University and the National Institutes of Health (NIH). BioIntervene’s founding team has pioneered the understanding of adenosine A3 receptor biology, with a focus on developing first-in-class, selective adenosine A3 receptor agonists.

CODA Biotherapeutics’ revolutionary chemogenetic platform aims to control the activity of cells to treat disease with chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable “switch” protein. Cells modified with the “switch” can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells.

Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.

Amphora Discovery Corporation operates as a biotechnology company. It provides integrated services to the pharmaceutical industry. The company's products and services include in vitro assay protocols, in vitro throughput screening and compound profiling services, custom assay development, enzymology services, and lead discovery/lead optimization partnering programs. It offers drug discovery contract research services, HTS, profiling and lead generation, and lead optimization solutions. The company serves pharmaceutical and biopharmaceutical companies, emerging biotechnology companies, and research foundations. Amphora Discovery Corporation was founded in 2001 and is headquartered in Durham, North Carolina. As of July 2008, Amphora Discovery Corporation operates as a subsidiary of Nanosyn Inc.

Epizyme is a biopharmaceutical company located in Cambridge, MA, that is focused on researching treatments for blood cancer and tumors. Founded in late 2007, the company has brought together premier academic and industry leaders to rapidly translate the exciting discoveries emerging from epigenetic research into specific programs that will produce important, novel, molecularly targeted drugs of the future.

NeuroTherapeutics Pharma, Inc., a biopharmaceutical company, develops therapeutics for patients suffering from central nervous system disorders. It focuses on epilepsy, neuropathic, and acute pain disorders of the nervous system. The company was incorporated in 2006 and is based in Chicago, Illinois.

Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.

Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.

TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to express defined TCR alpha/beta chains. TCR2 was founded by Dr. Patrick Baeuerle and MPM Capital. It has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world.

CODA Biotherapeutics’ revolutionary chemogenetic platform aims to control the activity of cells to treat disease with chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable “switch” protein. Cells modified with the “switch” can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells.

Xoft, Inc. develops electronic brachytherapy (eBx) systems for radiation oncology applications. It offers Axxent Controller that utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed. The company also provides Axxent balloon applicator, a treatment solution for accelerated partial breast irradiation; Axxent vaginal applicator that enables radiation oncologists to perform vaginal brachytherapy; and Axxent surface applicator that enables radiation oncologists to treat surface lesions. In addition, it offers accessories, such as physics accessory kits, personnel protective shields, procedure accessory packs, patient care kits, applicator clamp and base plates, and vacuum pumps, as well as FlexiShield, which drapes over the patient treatment area to reduce radiation transmission to nearby healthy tissue and organs. The company's products are used to treat early stage breast cancer, skin cancer, and endometrial cancer. It offers its products through physicians and distributors in Europe. Xoft, Inc. was formerly known as Xoft microTube, Inc. and changed its name in September 2004. The company was founded in 1998 and is based in Sunnyvale, California.

Xoft, Inc. develops electronic brachytherapy (eBx) systems for radiation oncology applications. It offers Axxent Controller that utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed. The company also provides Axxent balloon applicator, a treatment solution for accelerated partial breast irradiation; Axxent vaginal applicator that enables radiation oncologists to perform vaginal brachytherapy; and Axxent surface applicator that enables radiation oncologists to treat surface lesions. In addition, it offers accessories, such as physics accessory kits, personnel protective shields, procedure accessory packs, patient care kits, applicator clamp and base plates, and vacuum pumps, as well as FlexiShield, which drapes over the patient treatment area to reduce radiation transmission to nearby healthy tissue and organs. The company's products are used to treat early stage breast cancer, skin cancer, and endometrial cancer. It offers its products through physicians and distributors in Europe. Xoft, Inc. was formerly known as Xoft microTube, Inc. and changed its name in September 2004. The company was founded in 1998 and is based in Sunnyvale, California.

Tercica Inc., a biotechnology company, engages in the development and commercialization of therapeutics for the treatment of endocrine and metabolic diseases. Its products include Increlex, an rDNA origin injection for the long-term treatment of children with short stature due to severe primary IGFD; and Somatuline Depot, a lanreotide injection for the treatment of adults with acromegaly. Tercica Inc. has strategic partnerships with Genentech and Ipsen SA. The company was founded in 2002 and is based in Brisbane, California. As of October 16, 2008, Tercica Inc. operates as a subsidiary of Ipsen S.A.

Ceregene is a private, San Diego-based biotechnology company focused on the treatment of major neurodegenerative disorders using the delivery of nervous system growth factors. Their clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor, which is about to enter Phase 2 studies for the treatment of Alzheimer's disease, and CERE-120, which recently completed a Phase 2 trial in Parkinson's disease and is currently being evaluated for future development. CERE-135 and CERE-140 are in preclinical development for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and ocular diseases, respectively.

Blade Therapeutics is a discovery stage drug development company. Their mission is to create antifibrotic treatment strategies that address a wide variety of congenital and acquired diseases of fibrosis. Their leadership team has extensive experience at developing drugs that treat fibrotic disorders. They are also partnering with international experts in order to identify and in-license cutting-edge technologies to build a robust pipeline of antifibrotic compounds.

23andMe, Inc. provides consumer genetics and research services. The company offers DNA analysis services through home-based saliva collection kit for consumers to access and understand the human genome. Its services include Health + Ancestry, a genetic insight into ancestry, traits, and health; and Ancestry + Traits, a DNA kit with an ancestry breakdown and 30+ trait reports. The company was founded in 2006 and is based in Sunnyvale, California. With an additional office in Mountain View, California.

PrimeraDx, Inc. offers multiplexed infectious disease assays. It provides Scalable Target Amplification Routine technology, which is a method for simultaneous quantitative measurement of multiple target nucleic acids. The company also offers ViraQuant, a multiplexed assay providing quantitative and simultaneous measurement of viruses; and FungiQuant Yeast and FungiQuant Mold, which are fungal panels for mycology testing. Its products are used in miRNA, DNA methylation, quantitative genotyping, gene expression, and viral load measurement applications. PrimeraDx, Inc. was founded in 2004 and is based in Mansfield, Massachusetts.

Hypnion is a neuroscience drug discovery and development company that develops novel therapeutics for the treatment of central nervous system disorders. The company develops treatments for sleep- and wake-alertness disorders and circadian rhythm abnormalities. Hypnion offers SCORE-2004, a drug discovery platform that is able to measure drugs’ impact on sleep and wake parameters. Hypnion is acquired by Eli Lilly and Company. Hypnion was founded in 2000 and is based in Worcester, Massachusetts.

Peptimmune is a privately held clinical stage biotechnology company focused on utilizing both novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders. The company is developing second generation therapeutics that are expected to result in safer and more effective products for obesity, multiple sclerosis, rheumatoid arthritis and pemphigus vulgaris.

Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life. Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging. Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.

Chiasma (Israel) ltd., is a biopharmaceutical company which develops oral drugs based on transient permeability enhancer system. The company offers oral octreotide acetate for the treatment of acromegaly. Its pipeline products include novel drugs which addresses unmet needs for well-defined markets. The company focuses primarily on orphan indications. The company was founded in 2001 and is based in Ness Ziona, Israel. Chiasma (Israel) ltd. operates as a subsidiary of Chiasma, Inc.

Recode Therapeutics, Inc., a biopharmaceutical company, develops precision medicines for pulmonary diseases. Its pipeline includes programs for primary ciliary dyskinesia and nonsense mutations in cystic fibrosis. The company’s non-viral lipid nanoparticle platform enables the delivery of various payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. Recode Therapeutics, Inc. was founded in 2015 and is based in Menlo Park, California.